ONConcept® has successfully completed the pivotal BE study for Nilotinib

HELM Human Nutrition & Divaks: Innovating together for a sustainable future

At Human Nutrition, our commitment is to drive innovation in the food industry through solutions that not only create value for our clients but also contribute to a more sustainable, innovative, and competitive food future. To achieve this, it is essential to collaborate with strategic suppliers who share our vision for transformation.

Our partnership with Divaks, a leading company in the development of Textured Insect Protein (TIP), represents a key opportunity to introduce new protein sources with high nutritional value and a low environmental impact. This collaboration reflects our mission to bring innovative, functional, and future-oriented ingredients to the industry.

Showroom: "The new era of proteins"

As part of our innovation and development strategy, Human Nutrition Europe team organized the "The new era of proteins" showroom in Barcelona, Spain, bringing together leading food industry companies to showcase the potential of Tenebrio Molitor protein.

Held at Skyfall Cocktail Club, the event allowed key customers in Europe to discover and experience firsthand the benefits of this ingredient, highlighting its high protein content, functionality in food formulations, and positive impact on sustainability. Through an immersive gastronomic experience, we presented various applications, from high-protein desserts to dishes inspired by international cuisine, demonstrating the versatility of this protein source in the food industry.

Building the future with innovative and sustainable suppliers

Our partnership with Divaks is just the beginning. Our goal is to continue strengthening our portfolio with ingredients that not only meet today’s market demands but also anticipate future consumer needs. Investing in innovative solutions is not just a business strategy, it is a responsibility that we embrace alongside our business partners.

A huge thank you to the entire HELM Human Nutrition team for making this transformation possible and for continuing to drive the future of food together!

ONConcept® announces the successful completion of a positive bioequivalence (BE) study in the European Union for Nilotinib. The study marks a significant milestone in our commitment to advancing pharmaceutical research and development in the field of Oncology.

The results demonstrate the efficacy of our formulation, covered by patent applications, and it allows us to file a dossier very soon with a potential launch in 2026.

This success reinforces our vision to providing timely and impactful solutions for patients globally, and it highlights ONConcept® commitment to improving patients’ health and positions us as a crucial provider for the future of oncology treatments.